Skip to content

Charged trastuzumab ADC plasma disposition

A reduced plasma PK model representing first-order elimination, concentration, half-life, and cumulative exposure of a positively charged trastuzumab-vc-MMAE ADC.

PK/PD of Positively Charged ADC in Mice ↗

Pharmaceutics

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How does a single concentration profile build cumulative exposure?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Starting example

Charged trastuzumab ADC plasma disposition

Charged trastuzumab ADC plasma disposition

Explore how the starting plasma concentration and first-order elimination rate determine charged trastuzumab ADC concentration, half-life, and cumulative plasma exposure.

0–168 hour

Scenario details

Charged trastuzumab ADC plasma disposition

Explore how the starting plasma concentration and first-order elimination rate determine charged trastuzumab ADC concentration, half-life, and cumulative plasma exposure.

Readouts

Drug concentration · nM
Drug concentration over the selected simulation window.
Exposure (AUC) · h*nM
Exposure (AUC) over the selected simulation window.
ADC half-life · Unit unavailable
ADC half-life over the selected simulation window.

Study purpose

  • How does the elimination rate determine plasma ADC concentration, half-life, and exposure?
Loading starting example…

Edit inputs

Model parameter

Elimination rate constant governing first-order loss from the modeled system.

1/h

Suggested: 0.00804–0.0241. You can explore beyond this range.

0.01609 → —
Simulation time
h
h

Time between reported samples.

h

Starting settings · Variation 1

Continue in the background and keep the result.

Biology

A scenario initializes charged trastuzumab ADC plasma concentration. The concentration declines by first-order elimination while its integral accumulates as plasma exposure.

How do initial charged-ADC concentration and elimination set plasma exposure?A scenario initializes charged trastuzumab ADC plasma concentration. The concentration declines by first-order elimination while its integral accumulates as plasma exposure.BIOLOGY OVERVIEWHow do initial charged-ADC concentration and elimination set plasma exposure?Initial plasma ADC: Scenario-initialized concentrationInitial plasma ADCScenario-initializedconcentrationFirst-order loss: Concentration-proportional decayFirst-order lossConcentration-proportionaldecayCumulative exposure: Integral of plasma concentrationCumulativeexposureIntegral of plasmaconcentrationPRIMARY READOUTSPlasma ADC concentrationPlasma ADC concentrationCumulative plasma exposureCumulative plasma exposureModeled half-lifeModeled half-life

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: Administration route, distribution, HER2 binding, payload release, tissue uptake, and tumor effects are outside this one-state decay model.

Modeled relationships (2)
  • Initial plasma ADC → First-order loss: first-order (loss)
  • Initial plasma ADC → Cumulative exposure: integrates C (production)

Modeled relationships: Initial plasma ADC to First-order loss: first-order (loss); Initial plasma ADC to Cumulative exposure: integrates C (production).

Primary readouts: Plasma ADC concentration; Cumulative plasma exposure; Modeled half-life.

Model details

1 parameters · 3 states · 3 equations · 6 derived outputs

Classification & API access
Therapeutic
Positively charged trastuzumab-vc-MMAE ADC, trastuzumab
Modality
Antibody–drug conjugate (ADC)
Target
HER2 / ERBB2
Disease / scope
HER2-positive preclinical tumor models
ParameterDefaultUnitDescription
Elimination rate constantkel_1_h0.0160898876404494371/hElimination rate constant governing first-order loss from the modeled system.

Related models

T-DM1 and T-DXd conditional intact-ADC pharmacokineticsZenocutuzumab PK and tumor-growth dynamicsSKB264 tumor-growth inhibitionPertuzumab fixed serum PK contexts

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics